Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05263999
Recruitment Status : Recruiting
First Posted : March 3, 2022
Last Update Posted : July 6, 2022
Biocon Limited
Information provided by (Responsible Party):

Brief Summary:
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease GVHD Acute-graft-versus-host Disease Acute GVHD aGVHD Biological: Itolizumab Drug: EQ001 Placebo Phase 3

Detailed Description:
This study will enroll 200 subjects at approximately 125 sites globally. Subjects will be randomized in a 1:1 ratio to active or placebo and will receive a total of 7 doses administered intravenously approximately every 2 weeks. The study follows the patients for a total of approximately 365 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Actual Study Start Date : April 29, 2022
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : November 2024

Arm Intervention/treatment
Experimental: Itolizumab (EQ001)
Itolizumab (EQ001) administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses.
Biological: Itolizumab
Itolizumab [Bmab600]
Other Names:
  • EQ001
  • Bmab600

Placebo Comparator: EQ001 Placebo
EQ001 Placebo administered in a blinded fashion by intravenous infusion every 2 weeks for a total of 7 doses
Drug: EQ001 Placebo
EQ001 Placebo

Primary Outcome Measures :
  1. The efficacy of itolizumab versus placebo as initial therapy for aGVHD in combination with corticosteroids in achieving early disease response. [ Time Frame: Day 29 ]
    Complete response at Day 29

Secondary Outcome Measures :
  1. Evaluate the durability of response to itolizumab versus placebo as initial therapy for aGVHD in combination with corticosteroids. [ Time Frame: Day 99 ]
    Durable Complete Response rate from Day 29 through Day 99

  2. Assess the impact of itolizumab versus placebo on other clinically relevant efficacy measures, [ Time Frame: Day 29 ]
    Overall Response Rates at Day 29

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Is willing and able to provide written informed consent/assent and to comply with all protocol procedures and assessments required for the study.
  2. Is age ≥12 years and >40kg at informed consent/assent.
  3. Has had an initial allogeneic HSCT for any indication using any graft source, donor source, conditioning regimen intensity or prophylaxis.
  4. Has evidence of myeloid engraftment
  5. Has a clinical diagnosis of aGVHD Grades III-IV or Grade II with LGI involvement based on Mount Sinai Acute GVHD International Consortium (MAGIC) grading criteria.
  6. Began systemic corticosteroid treatment for aGVHD ≤72 hours prior to the start of study drug dosing AND must receive 2 mg/kg/day methylprednisolone or equivalent on Day 1.

Exclusion Criteria:

  1. Evidence of morphological relapsed, progressive, persistent, or untreated malignancy, with the exception of nonmelanoma skin cancer and in situ ductal carcinoma of the breast.
  2. An unplanned donor lymphocyte infusion for persistent or recurrent malignancy after HSCT.
  3. Evidence of persistent molecular disease requiring treatment that was not specified prior to HSCT.
  4. Evidence of cGVHD or overlap syndrome
  5. Use of immunosuppressants other than corticosteroids for the treatment of aGVHD.
  6. Use of any systemic corticosteroids of >0.5 mg/kg/day methylprednisolone or equivalent for any indication other than aGVHD within 7 days before the onset of aGVHD.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05263999

Layout table for location contacts
Contact: Clinical Trial Manager 858-240-1200

Layout table for location information
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
United States, Massachusetts
Dana-Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
United States, Pennsylvania
University of Pennsylvania Abramson Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Recruiting
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Sarah Cannon Research Institute, LLC (SCRI) Recruiting
Nashville, Tennessee, United States, 37203
Canada, British Columbia
Vancouver Coastal Health Authority Not yet recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
Biocon Limited
Layout table for investigator information
Study Director: Maple Fung, MD Equillium, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Equillium Identifier: NCT05263999    
Other Study ID Numbers: EQ-100-02
First Posted: March 3, 2022    Key Record Dates
Last Update Posted: July 6, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases